N Safai1, T Suvitaival1, A Ali1, P Spégel2,3, M Al-Majdoub2, B Carstensen1, H Vestergaard1,4, M Ridderstråle1,2,5. 1. Steno Diabetes Center Copenhagen, Gentofte, Denmark. 2. Unit of Molecular Metabolism, Department of Clinical Sciences Malmö, Lund University, Malmö. 3. Centre for Analysis and Synthesis, Department of Chemistry, Lund University, Lund, Sweden. 4. Novo Nordisk Foundation of Basic Metabolic Research, University of Copenhagen, Copenhagen. 5. Novo Nordisk A/S, Søborg, Denmark.
Abstract
AIM: Metformin is the first-line treatment for Type 2 diabetes. However, not all people benefit from this drug. Our aim was to investigate the effects of metformin on the plasma metabolome and whether the pretreatment metabolite profile can predict HbA1c outcome. METHODS: Post hoc analysis of the Copenhagen Insulin and Metformin Therapy (CIMT) trial, a multicentre study from May 2008 to December 2012, was carried out. We used a non-target method to analyse 87 plasma metabolites in participants with Type 2 diabetes (n = 370) who were randomized in a 1 : 1 ratio to 18 months of metformin or placebo treatment. Metabolites were measured by liquid chromatography-mass spectrometry at baseline and at 18-month follow-up and the data were analysed using a linear mixed-effect model. RESULTS: At baseline, participants who were on metformin before the trial (n = 312) had higher levels of leucine/isoleucine and five lysophosphatidylethanolamines (LPEs), and lower levels of carnitine and valine compared with metformin-naïve participants (n = 58). At follow-up, participants randomized to metformin (n = 188) had elevated levels of leucine/isoleucine and reduced carnitine, tyrosine and valine compared with placebo (n = 182). At baseline, participants on metformin treatment with the highest levels of carnitine C10:1 and leucine/isoleucine had the lowest HbA1c (P-interaction = 0.02 and 0.03, respectively). This association was not significant with HbA1c at follow-up. CONCLUSIONS:Metformin treatment is associated with decreased levels of valine, tyrosine and carnitine, and increased levels of leucine/isoleucine. None of the identified metabolites can predict the HbA1c -lowering effect of metformin. Further studies of the association between metformin, carnitine and leucine/isoleucine are warranted.
RCT Entities:
AIM: Metformin is the first-line treatment for Type 2 diabetes. However, not all people benefit from this drug. Our aim was to investigate the effects of metformin on the plasma metabolome and whether the pretreatment metabolite profile can predict HbA1c outcome. METHODS: Post hoc analysis of the Copenhagen Insulin and Metformin Therapy (CIMT) trial, a multicentre study from May 2008 to December 2012, was carried out. We used a non-target method to analyse 87 plasma metabolites in participants with Type 2 diabetes (n = 370) who were randomized in a 1 : 1 ratio to 18 months of metformin or placebo treatment. Metabolites were measured by liquid chromatography-mass spectrometry at baseline and at 18-month follow-up and the data were analysed using a linear mixed-effect model. RESULTS: At baseline, participants who were on metformin before the trial (n = 312) had higher levels of leucine/isoleucine and five lysophosphatidylethanolamines (LPEs), and lower levels of carnitine and valine compared with metformin-naïve participants (n = 58). At follow-up, participants randomized to metformin (n = 188) had elevated levels of leucine/isoleucine and reduced carnitine, tyrosine and valine compared with placebo (n = 182). At baseline, participants on metformin treatment with the highest levels of carnitine C10:1 and leucine/isoleucine had the lowest HbA1c (P-interaction = 0.02 and 0.03, respectively). This association was not significant with HbA1c at follow-up. CONCLUSIONS:Metformin treatment is associated with decreased levels of valine, tyrosine and carnitine, and increased levels of leucine/isoleucine. None of the identified metabolites can predict the HbA1c -lowering effect of metformin. Further studies of the association between metformin, carnitine and leucine/isoleucine are warranted.
Authors: Meghana D Gadgil; Alka M Kanaya; Caroline Sands; Matthew R Lewis; Namratha R Kandula; David M Herrington Journal: Diabet Med Date: 2020-12-25 Impact factor: 4.359
Authors: Evan L Brittain; Kevin Niswender; Vineet Agrawal; Xinping Chen; Run Fan; Meredith E Pugh; Todd W Rice; Ivan M Robbins; Haocan Song; Christopher Thompson; Fei Ye; Chang Yu; He Zhu; James West; John H Newman; Anna R Hemnes Journal: J Am Heart Assoc Date: 2020-11-10 Impact factor: 5.501
Authors: Stephanie T Chung; Samantha T Matta; Abby G Meyers; Celeste K Cravalho; Alfredo Villalobos-Perez; Joshua M Dawson; Vandhna R Sharma; Maureen L Sampson; James D Otvos; Sheela N Magge Journal: Front Endocrinol (Lausanne) Date: 2021-05-18 Impact factor: 5.555
Authors: Natthida Sriboonvorakul; Wirichada Pan-Ngum; Kittiyod Poovorawan; Sant Muangnoicharoen; Lauren M Quinn; Bee K Tan Journal: J Clin Med Date: 2021-11-20 Impact factor: 4.241
Authors: Koen F Dekkers; Sergi Sayols-Baixeras; Marju Orho-Melander; Tove Fall; Gabriel Baldanzi; Christoph Nowak; Ulf Hammar; Diem Nguyen; Georgios Varotsis; Louise Brunkwall; Nynne Nielsen; Aron C Eklund; Jacob Bak Holm; H Bjørn Nielsen; Filip Ottosson; Yi-Ting Lin; Shafqat Ahmad; Lars Lind; Johan Sundström; Gunnar Engström; J Gustav Smith; Johan Ärnlöv Journal: Nat Commun Date: 2022-09-23 Impact factor: 17.694